Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

BACKGROUND: Several monoclonal antibodies for the treatment of Alzheimer’s disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. METHODS: Here we describe the first clinical study with BAN2401. Safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Logovinsky, Veronika, Satlin, Andrew, Lai, Robert, Swanson, Chad, Kaplow, June, Osswald, Gunilla, Basun, Hans, Lannfelt, Lars
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822297/
https://www.ncbi.nlm.nih.gov/pubmed/27048170
http://dx.doi.org/10.1186/s13195-016-0181-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4822297/
https://www.ncbi.nlm.nih.gov/pubmed/27048170
http://dx.doi.org/10.1186/s13195-016-0181-2

Ejemplares similares